Latest Tax Rebates News

Algorae Pharmaceuticals has secured a significant A$318,771 R&D tax incentive rebate from the Australian Taxation Office, providing a non-dilutive cash injection to advance its AI-driven drug discovery programs.

Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.

Ardea Resources has received a $1.2 million R&D tax incentive rebate from the Australian Government, reinforcing its innovative work at the Kalgoorlie Nickel Project and strengthening its financial position.

Recce Pharmaceuticals reports strong Phase II clinical trial results for its topical anti-infective R327G, achieving a 93% efficacy rate in treating ABSSSI, alongside a significant capital raise to fund upcoming Phase III trials.

Environmental Clean Technologies Limited has commissioned batch-scale granulation equipment and produced its first 12 tonnes of COLDry Fertiliser, while securing $1.75 million in capital through placements and convertible notes to support ongoing project financing.

South Harz Potash Limited has progressed its Ohmgebirge project with key steps including advancing the Sollstedt mine acquisition, securing A$500,000 in new equity, and pursuing strategic funding avenues such as German R&D rebates and European Union grants.

International Graphite's March 2025 quarterly report highlights strong geopolitical tailwinds and government backing for its Springdale Graphite Project and Collie processing facilities, positioning the company as a key player in the critical minerals supply chain.

Empire Energy Group is advancing its Carpentaria-5H well hydraulic stimulation scheduled for June 2025, alongside preparations for the Carpentaria Gas Plant construction, aiming to commence gas sales from EP187 by late 2025 or early 2026.

Blue Energy has resolved a significant legal hurdle by securing an amended Environmental Authority for its Sapphire asset, enabling progression of the Petroleum Lease 1034 and continued pilot production testing despite operational interruptions.

Constellation Technologies Limited reports sustained sales growth and positive cash flow in Q3 2025, driven by its Callisto Food Safety & Compliance system and strategic market expansion.

EMVision Medical Devices has commenced the pivotal clinical trial for its emu™ bedside brain scanner aimed at FDA clearance, while advancing its First Responder device through successful aeromedical testing and ethics approvals. The company maintains strong cash reserves of $12.58 million to support ongoing innovation and clinical activities.

Identitii Limited advances its BNDRY platform with new agreements targeting hospitality and payments sectors, appoints Tim Phillipps as Executive Chair, and reports stable cash flow amid ongoing patent litigation.